Wave Life Sciences Ltd. (WVE)
Nasdaq: WVE · Pharmaceutical Preparations · Singapore, SG · filing with the SEC since 2015
Who owns Wave Life Sciences Ltd.
As filed with the SECHolders of 5% or more
3
RA Capital Management, L.P. holds 16.8% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D/A filed Aug 11, 2026 says.
Directors and officers
17
report now, of 26 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Aug 11, 2026 · Common Stock, $0.001 par value per share · 17.1% in Apr 17, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock · 0% in Oct 27, 2026
Maverick Capital, Ltd.
SCHEDULE 13G/A · filed Feb 14, 2025 · $0 Par Value Ordinary Shares
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · reported falling below 5%, from 8.5% in Feb 5, 2026
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed May 13, 2026 · Ordinary Shares, no par value · reported falling below 5%, from 5.35% in Feb 12, 2026
What WVE reports owning in othersstakes of 5% or more, and other ties
Wave Life Sciences Ltd. reports no stake in another company in the record.
Insider tradesForm 4
47sales
5purchases
43sales on a scheduled plan
11people selling
$16.2Msold, in dollars
$54.6Mbought, in dollars
Open-market trades on Form 4 from Oct 7, 2025 to Oct 7, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 7, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window13 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Francis Chris | SVP, Corporate Development, Head of Emerging Areas | 14 | $7.1M | 13 | 0 | $0 |
| Moran Kyle | Chief Financial Officer | 7 | $4.2M | 6 | 0 | $0 |
| Tan Aik Na | director | 9 | $1.8M | 9 | 0 | $0 |
| Henry Christian O | director | 4 | $1.4M | 4 | 0 | $0 |
| Rawcliffe Adrian | director | 3 | $800,000 | 3 | 0 | $0 |
| Verdine Gregory L. | director | 2 | $300,000 | 2 | 0 | $0 |
| Corrigan Mark | director | 2 | $200,000 | 2 | 0 | $0 |
| Wagner Heidi L | director | 3 | $200,000 | 3 | 0 | $0 |
| Bolno Paul | President and CEO | 1 | $100,000 | 0 | 0 | $0 |
| Ra Capital Management, LLC | director | 0 | $0 | 0 | 5 | $54.6M |
| Gsk PLC | 10% owner | 0 | $0 | 0 | 1 | $27.9M |
| Vargeese Chandra | Chief Technology Officer, Head of Platform Discovery Sciences | 1 | $0 | 0 | 0 | $0 |
| Takanashi Ken | director | 1 | $0 | 1 | 0 | $0 |